Related Experiment Video

Updated: May 27, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Combination therapy for renal cell cancer: what are possible options?

Napoleon Santos1, Justin B Wenger, Pamela Havre

  • 1Division of Hematology/Oncology, Department of Internal Medicine, University of Florida Shands Cancer Center, University of Florida, Gainesville, FL, USA.

Oncology
|November 17, 2011
PubMed

Insights

Antiangiogenic therapies show promise for renal cell carcinoma (RCC) but offer modest benefits. Novel combination therapies are being explored to improve efficacy in treating this cancer.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Antiangiogenic therapies, including bevacizumab and tyrosine kinase inhibitors (sorafenib, sunitinib, pazopanib), are FDA-approved for renal cell carcinoma (RCC).
  • Clinical benefits of these agents in RCC are often heterogeneous, modest, and short-lived.
  • Previous combination targeted therapies have yielded limited efficacy or unacceptable toxicities.

Purpose of the Study:

  • To explore novel combination therapies for renal cell carcinoma (RCC).
  • To improve the efficacy of antiangiogenic treatments in RCC.
  • To leverage recent advances in understanding tumor angiogenesis and resistance mechanisms.

Main Methods:

  • Review of current antiangiogenic therapies for RCC.
  • Analysis of molecular mechanisms in tumor angiogenesis and resistance.
  • Exploration of novel targeted drug discovery for combination therapy.

Main Results:

  • Current antiangiogenic drugs show variable efficacy in RCC patients.
  • Combination therapies have faced challenges with efficacy and toxicity.
  • Advances in molecular understanding pave the way for new treatment strategies.

Conclusions:

  • Further research into novel combination therapies is crucial for improving RCC treatment outcomes.
  • Targeted drug discovery holds promise for overcoming limitations of current antiangiogenic treatments.
  • A deeper understanding of angiogenesis and resistance mechanisms is key to developing more effective RCC therapies.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...